At 8.2% CAGR, the North America Lung Cancer Screening Market is projected to be worth US$ 1,811.48 million by 2030, says Business Market Insights

According to Business Market Insights research, the North America lung cancer screening market was valued at US$ 965.41 million in 2022 and is expected to reach US$ 1,811.48 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Rising lung cancer incidences is the critical factor attributed to the North America lung cancer screening market.

One of the dominant trends in the market for lung cancer diagnostics is the use of cutting-edge technologies. Liquid biopsies and genomic profiling will become increasingly popular, allowing for the more accurate and non-invasive detection of cancer-related mutations and biomarkers. By analyzing complicated medical data and images, AI and machine learning will improve diagnostic accuracy and help radiologists spot indications to lung cancer. Additionally, multi-modal approaches that combine different diagnostic modalities for comparative assessment will receive more attention. These developments will result in earlier and more precise diagnoses of lung cancer, enabling prompt interventions and better patient outcomes.

On the contrary, high cost of lung cancer screening hampers the North America lung cancer screening market.  

Based on cancer type, the North America lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 81.8% share of North America lung cancer screening market in 2022, amassing US$ 789.70 million. It is projected to garner US$ 1,460.35 million by 2030 to expand at 8.0% CAGR during 2022–2030.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. The low dose computed tomography (LDCT) segment held 52.4% share of North America lung cancer screening market in 2022, amassing US$ 505.81 million. It is projected to garner US$ 981.55 million by 2030 to expand at 8.6% CAGR during 2022–2030.

Based on age group, the North America lung cancer screening market is segmented into 50 and older and below 50. The 50 and older segment held 89.9% share of North America lung cancer screening market in 2022, amassing US$ 868.34 million. It is projected to garner US$ 1,618.33 million by 2030 to expand at 8.1% CAGR during 2022–2030.

Based on end user, the North America lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 46.1% share of North America lung cancer screening market in 2022, amassing US$ 444.95 million. It is projected to garner US$ 807.02 million by 2030 to expand at 7.7% CAGR during 2022–2030.

Based on country, the North America lung cancer screening market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 92.6% share of North America lung cancer screening market in 2022. It was assessed at US$ 894.23 million in 2022 and is likely to hit US$ 1,687.93 million by 2030, exhibiting a CAGR of 8.3% during 2022–2030.

Key players operating the North America lung cancer screening market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, Siemens AG, bioAffinity Technologies, Inc, CVS Health, and Lunglife AI Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com